A phase II study of capecitabine (Cape) or 5-fluorouracil (5-FU) with pegylated interferon alpha-2b (Peg-IFNA-2b) in unresectable/metastatic cutaneous squamous cell carcinoma (CSCC).

Jameel Muzaffar,Nikhil I. Khushalani,Jeffery S. Russell,Janaki Parameswaran,Kedar Kirtane,Janis de la Iglesia,Robbert J. C. Slebos,Christine H. Chung

A phase II study of capecitabine (Cape) or 5-fluorouracil (5-FU) with pegylated interferon alpha-2b (Peg-IFNA-2b) in unresectable/metastatic cutaneous squamous cell carcinoma (CSCC).

2019

Jameel Muzaffar
Nikhil I. Khushalani
Jeffery S. Russell
Janaki Parameswaran
Kedar Kirtane
Janis de la Iglesia
Robbert J. C. Slebos
Christine H. Chung

e21020Background: Patients (pts) with unresectable/metastatic CSCC have a poor prognosis, and until recently had limited treatment options. Based on encouraging efficacy in case report series, we c...

Keywords:

Capecitabine
Cutaneous squamous cell carcinoma
Fluorouracil
Pegylated interferon alpha-2b
Phases of clinical research
PEG ratio
Cancer research
Pathology
Medicine
treatment options
Internal medicine
Oncology
poor prognosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations